EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study

Tamás Resál, Péter Bacsur, Csilla Keresztes, Anita Bálint, Renáta Bor, Anna Fábián, Bernadett Farkas, Kostas Katsanos, George Michalopoylos, Davide Giuseppe Ribaldone, Mohamed Attauabi, Mirabella Zhao iD und 33 weitere

Inflammatory Bowel Diseases · 02.05.2024 · 30 (5) · 768-779

DOI: 10.1093/ibd/izad135 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 05.08.2023. Verfasst von Tamás Resál und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyrimidines, Piperidines. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hungarian Scientific Research, National Research, Development and Innovation Office, New National Excellence Program of the Ministry of Human Capacities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC.

Methods

This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed.

Results

A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported.

Conclusions

TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePyrimidinesPiperidinesHumansMaleRetrospective StudiesFemaleMiddle AgedAdultColectomyTreatment OutcomeSeverity of Illness IndexRemission InductionFollow-Up StudiesProtein Kinase Inhibitors

Stichwörter der Autor:innen

acute severe ulcerative colitismoderate-to severe ulcerative colitistofacitinib

Substanzen

tofacitinibPyrimidinesPiperidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
  • Department for Medical Communication and Translation Studies, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
  • Gastroenterology Department, General Hospital of Athens G. Gennimatas, Athens, Greece.
  • Department of Medical Sciences, University of Turin, Turin, Italy.
  • Department of Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.

ORCID-Profile: Mirabella Zhao, Cristina Bezzio, Alessandro Armuzzi, David Drobne, Panu Wetwittayakhlang, Tamás Molnár

Förderung

  • Hungarian Scientific Research
  • National Research, Development and Innovation Office
  • New National Excellence Program of the Ministry of Human Capacities
  • Janos Bolyai Research
  • Géza Hetényi Research
  • Albert Szent-Györgyi Medical School, University of Szeged

Zitieren

APA

Resál, T., Bacsur, P., Keresztes, C., Bálint, A., Bor, R., Fábián, A., Farkas, B., Katsanos, K., Michalopoylos, G., Ribaldone, D. G., Attauabi, M., Zhao, M., Barak, H. A., Yanai, H., Bezzio, C., Rispo, A., Castiglione, F., Bar-Gil Shitrit, A., Pugliese, D., …, & Molnár, T. (2024). Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflammatory Bowel Diseases, 30(5), 768-779. https://doi.org/10.1093/ibd/izad135

Vancouver

Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, et al. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflammatory Bowel Diseases. 2024;30(5):768-779. doi:10.1093/ibd/izad135

BibTeX
@article{Resl2024,
  author = {Resál, Tamás and Bacsur, Péter and Keresztes, Csilla and Bálint, Anita and Bor, Renáta and Fábián, Anna and Farkas, Bernadett and Katsanos, Kostas and Michalopoylos, George and Ribaldone, Davide Giuseppe and Attauabi, Mohamed and Zhao, Mirabella and Barak, Hadar Amir and Yanai, Henit and Bezzio, Cristina and Rispo, Antonio and Castiglione, Fabiana and Bar-Gil Shitrit, Ariella and Pugliese, Daniela and Armuzzi, Alessandro and Savarino, Edoardo Vincenzo and Kolar, Martin and Lukáš, Milan and Chashkova, Elena and Filip, Rafał and Rozieres, Aurore and Nancey, Stéphane and Krznarić, Željko and Schäfer, Eszter and Szamosi, Tamás and Sarlós, Patrícia and Franko, Matej and Drobne, David and Knyazev, Oleg V and Kagramanova, Anna V and Limdi, Jimmy and Wetwittayakhlang, Panu and Lakatos, Peter L and Maharshak, Nitsan and Bannon, Lian and Nyári, Tibor and Szepes, Zoltán and Farkas, Klaudia and TFB Study Group, TFB Study Group and Molnár, Tamás},
  title = {Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {5},
  pages = {768--779},
  doi = {10.1093/ibd/izad135}
}
Kostenlos starten →